Penthrox IND approved in China
21 November 2019
ASX ANNOUNCEMENT
Penthrox IND approved in China
Medical Developments International Limited (ASX: MVP) is delighted to announce the Chinese National Medical Product Administration (NMPA) has approved the opening of MVP’s Investigative New Drug (IND) application. This application is a critical step and building block to having Penthrox approved for sale in China.
MVP’s submission in China is to have Penthrox approved for two separate indications. The first is for Trauma Pain and the second for Procedural Pain.
For more information please click on the follow link – China approves Penthrox IND